NIMHD Forecasts a $3M Limited-Competition U19 for American Indian and Alaska Native Cancer Research — RFA-MD-27-001

The National Institute on Minority Health and Health Disparities has forecast a limited-competition U19 for academic PIs at NCI-designated cancer centers, offering an estimated $3 million with applications due January 25, 2027, per the grants.gov listing for RFA-MD-27-001.

That forecast went live on July 16, 2026, which means the research teams best positioned to win this award have roughly six months before the full solicitation even publishes — and every one of those months matters, because a U19 is not a grant you assemble in a weekend.

What RFA-MD-27-001 actually funds

The forecast for RFA-MD-27-001 describes a Notice of Funding Opportunity to "support research that addresses the prevention, diagnosis, and treatment of cancers among American Indians and Alaska Natives (AI/AN), particularly those living in rural communities." The stated research objectives target overall cancer incidence and mortality, with the explicit goal of producing findings that are "applicable and impactful in improving cancer outcomes in AI/AN patients and their families."

The mechanics, pulled directly from the grants.gov record, are unusually concrete for a forecast:

• Mechanism: U19 Research Program Cooperative Agreement, Clinical Trial Optional
• Estimated funding: $3,000,000
• Anticipated awards: one
• Funding instrument: cooperative agreement (not a standard grant — NIH staff are substantially involved)
• Assistance listing: 93.307, Minority Health and Health Disparities Research
• Estimated synopsis posting: November 25, 2026
• Estimated application due date: January 25, 2027
• Estimated award and project start: September 30, 2027 (fiscal year 2027)
• Cost sharing: not required

The administering office is the NIMHD Division of Community Health and Population Science (DCHPS) scientific team, reachable at NIMHDDCHPSScientificTeam@mail.nih.gov. This is a reissue of the program NIMHD ran as RFA-MD-24-009, whose applications were due August 2, 2024 — so there is a funded predecessor cohort to study, and there is institutional memory inside NIMHD about what a competitive application looked like last cycle.

Why "limited competition" and "U19" together change who can realistically apply

Two phrases in the title do most of the gatekeeping work, and PIs should read them literally before investing a single hour.

"Limited Competition" means NIMHD will invite applications only from organizations that meet a narrowly defined eligibility profile — this is not an open call. The grants.gov applicant-type list names public and private institutions of higher education and 501(c)(3) nonprofits, but the predecessor RFA-MD-24-009 scoped the real pool much tighter: NCI-designated cancer centers with existing community outreach infrastructure and established collaborations with AI/AN populations. If your institution does not already have a funded relationship with tribal or Alaska Native communities and a cancer center backbone, the limited-competition framing is a signal that the door is effectively closed for this cycle — and that the honest move is to start building the partnerships now for the next one.

"U19" is the second filter. A U19 is a multi-component research program cooperative agreement — it funds a coordinated set of research projects and shared cores under a single administrative umbrella, not one investigator's aim-driven R01. That structure demands an administrative core, a lead PI (or multiple PIs) who can manage several project leads, and genuine institutional commitment to governance. The "cooperative agreement" designation matters too: NIH program staff are written into the award as substantial scientific partners, so applicants should expect ongoing federal involvement in direction and milestones rather than the arms-length relationship of a standard grant.

Read together, the two phrases describe a specific applicant: a cancer center with a standing AI/AN community-outreach program, the infrastructure to run a multi-project cooperative agreement, and a leadership team that has done this before.

The cancer burden this NOFO is built to address

The scientific rationale behind the initiative is not abstract. American Indian and Alaska Native populations carry disproportionately high incidence and mortality across several cancers — liver, stomach, kidney, lung, colorectal, and female breast cancer — relative to non-Hispanic white populations in most regions of the United States. The disparities widen in rural communities, where distance to NCI-designated care, workforce shortages, and fractured screening pathways compound biological and access-related risk.

That is why the NOFO language singles out "those living in rural communities" and frames success not as a publication count but as findings "applicable and impactful" for patients and families. For a review panel, that phrasing is a scoring signal: applications that stop at characterizing disparities will lose to applications that build a credible path from research to changed outcomes — screening uptake, earlier-stage diagnosis, treatment completion — inside real AI/AN communities. Tribal engagement, data sovereignty agreements, and community-defined priorities are not garnish on this application; they are the load-bearing structure.

Reading the forecast timeline: narrow on paper, generous in practice

The dates look tight — synopsis in late November 2026, applications due January 25, 2027 — a roughly eight-week window from full publication to submission. For a single-PI R01 that would be uncomfortable. For a U19 it would be impossible if you started when the synopsis dropped.

But the forecast exists precisely so that teams can start now. Everything that makes a U19 competitive is pre-solicitation work: securing tribal partnership commitments and letters of support, aligning institutional review boards and any tribal IRB or research-review board, drafting data-governance and biospecimen agreements, recruiting project leads across the components, and building the administrative core budget. None of that requires the final NOFO text. The forecast even tells you the assistance listing (93.307) and the estimated $3 million ceiling, which is enough to model a realistic budget across the anticipated project period.

One caution: this is a forecast, and NIH forecasts move. Treat November 25, 2026 as a planning anchor, not a guarantee, and expect the full NOFO to add specifics the forecast omits — direct-cost caps per component, project-period length, page limits, and a letter-of-intent date, which NIH customarily sets about 30 days before the due date. Watch the NIH Guide for the RFA-MD-27-001 posting, and set an alert on the grants.gov record so a revision doesn't slip past you.

The budget math and the predecessor cohort

A U19's budget math is where good science teams stumble. The estimated $3 million is a program-level figure, and on a multi-component cooperative agreement it has to stretch across an administrative core, a shared community-engagement or data core, and two or more research projects — before a dollar reaches a bench or a clinic. Reviewers notice when a budget is really one R01 wearing a U19 costume: a single dominant project with token cores attached. The predecessor RFA-MD-24-009 was corrected on budget after posting (NOT-MD-24-020), a reminder that even NIMHD refines these numbers, so build your components with headroom and be ready to rescale when the full NOFO fixes the direct-cost caps per year.

The predecessor cohort is your best available intelligence. Because RFA-MD-24-009 was awarded in 2024, there is now a funded program you can study through NIH RePORTER — its aims, its cores, its partner communities, and its PIs. For a limited competition where the eligible pool is small and often overlapping cycle to cycle, understanding what NIMHD already funded tells you both what a winning application looked like and where the white space is. Do not propose to rebuild what the 2024 award is already doing; propose the complement, the extension, or the population the prior cohort could not reach.

Where this sits in the 2027 cancer-equity funding wave

RFA-MD-27-001 is not an isolated announcement — it is one node in a coordinated push to fund community-anchored cancer research for underserved populations in the 2027 cycle. The most direct companion is NCI's community oncology renewal, which we covered when NCI's NCORP 2027 renewal opened $147.5 million across three RFAs. The two programs are complementary: NCORP builds the distributed trial-and-care-delivery network, while the NIMHD U19 funds the disparities-focused research program that can plug into and study that network for AI/AN communities specifically.

For a cancer center weighing where to put its grant-writing capacity, the pairing is strategic. A team already competing in the NCORP renewal has much of the community-engagement infrastructure the NIMHD U19 rewards — and can position the two applications so that a win in one strengthens the other rather than duplicating effort. That is the difference between chasing announcements one at a time and reading the funding landscape as a system.

What to do before the synopsis drops

If you are a PI at an NCI-designated cancer center with — or building toward — an AI/AN community-outreach program, the productive moves over the next six months are partnership commitments, governance paperwork, and component-team recruitment, not prose. Start by confirming you can see every related and successor NIMHD cancer-disparities solicitation in one place: search NIMHD American Indian and Alaska Native cancer funding on Granted to track RFA-MD-27-001 alongside the companion NCORP and cancer-equity mechanisms, and set the groundwork now so that when the full NOFO publishes on or around November 25, 2026, your only remaining job is to write.